CClinicalTrials.gg
RecruitingNCT06693700Updated Aug 27, 2026

A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home

An interventional study of Indoor Air Quality Monitor AirGradient ONE in Smoking, Smoking Cessation and Smoking Reduction, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.

02

Conditions studied

  • Smoking
  • Smoking Cessation
  • Smoking Reduction
  • Smoking Habit
  • Smoking Behaviors
  • Smoking, Tobacco
  • Smoking, Cigarette
  • Smoking (Tobacco) Addiction
  • Tobacco Use
  • Tobacco Smoking

Keywords

  • smoking
  • smoking cessation
  • smoking reduction
  • smoking habit
  • smoking behaviors
  • smoking, tobacco
  • smoking, cigarette
  • smoking (tobacco) addiction
  • tobacco use
  • tobacco smoking
  • air quality
  • indoor air quality monitoring devices
  • 24-260
  • Memorial Sloan Kettering Cancer Center
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adult (aged >18 years) MSK patients as per the EHR
  • Has been referred and enrolled in the MSK TTP and completed the initial counseling session as per the TTP clinical database
  • Reports current (within the past 30 days) tobacco use (i.e., cigarettes and/or any other tobacco products) as per the TTP Intake form
  • Must be English-speaking in the EHR
  • Must be reachable by phone as per self-report
  • Must have Wi-Fi available at home as per self-report

Exclusion criteria

Exclusion Criteria:

  • Patient reports that no smoking is allowed, by them or anyone else, in the home as per the TTP intake form and/or per self-report
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    MSK Participants who are current smokers

    10 MSK participants who are current smokers and receiving tobacco treatment will be enrolled.

    Other: Indoor Air Quality Monitor AirGradient ONE

Interventions

  • OtherIndoor Air Quality Monitor AirGradient ONE

    Participants will be asked to set up an Indoor Air Quality Monitor AirGradient ONE (Model: I-9PSL) which is an award winning commercially available indoor air quality monitor designed to enable anyone to monitor their air quality in their home for about 60 days (8 weeks). Indoor air pollution levels within participating households will be measured using these AQMs.

05

What researchers measure

Primary outcomes

  1. Percentage of participants using the air quality monitoring device for 14 consecutive days

    Assess the feasibility and acceptability of collecting environmental data on biomarkers of household air quality (AQ) and smoke exposure using low-cost, AQMs as an intermediate endpoint of a smoke-free-home.

    Time frame: up to 8 weeks

  2. Percentage of participants who attend the study-specific smoke-free workshop sessions

    Assess the feasibility and acceptability of tobacco treatment adherence among individuals diagnosed with cancer.

    Time frame: Up to 8 weeks

06

Study locations

7 of 8 sites recruiting
  • Memorial Sloan Kettering Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
  • Memorial Sloan Kettering Bergen (Consent only)
    Montvale, New Jersey 07645, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
  • Memorial Sloan Kettering Suffolk-Commack (Consent only)
    Commack, New York 11725, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
  • City College of New York (Data Collection AND Data Analysis)
    New York, New York 10031, United States
    Not yet recruiting
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    New York, New York 10065, United States
    • Gleneara Bates-Pappas, PhD,LMSW · Contact · 212-610-0507
    Recruiting
  • Memorial Sloan Kettering Nassau (Consent only)
    Uniondale, New York 11553, United States
    • Gleneara Bates-Pappas, PhD, LMSW · Contact · 212-610-0507
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

08

Registry details

Key details

Study ID
NCT06693700
Lead sponsor
Memorial Sloan Kettering Cancer Center
Responsible party
Sponsor
First posted
Nov 18, 2024
Start date
Nov 14, 2024
Primary completion
Nov 14, 2027 (estimated)
Completion
Nov 14, 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Gleneara Bates-Pappas, PhD, LMSW
Contact
batespag@mskcc.org
212-610-0507
Michael Bellamy, PhD
Contact
bellamym@mskcc.org
212-639-2045
Gleneara Bates-Pappas, PhD, LMSW
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion